Ardelyx(ARDX) ZACKS·2025-02-20 14:45分组1 - Ardelyx reported quarterly earnings of 0.12 per share a year ago, indicating a significant improvement [1] - The company achieved revenues of 34.36 million year-over-year [2] - Ardelyx has surpassed consensus EPS estimates three times in the last four quarters and has topped consensus revenue estimates four times in the same period [1][2] 分组2 - Ardelyx shares have increased approximately 25.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 4.5% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is -74.79 million, and for the current fiscal year, it is -347.85 million [7] 分组3 - The Medical - Drugs industry, to which Ardelyx belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5][6]